Streetwise Reports' Article Archives — December 2023 back to current month (17)
Contracts Add Thousands of Patients to Telehealth Platform (12/28/2023)
Reliq Health Technologies Inc. says it has signed new contracts with 10 physician practices in three states to add thousands more patients to its iUGO telehealth platform.
Co.'s Breast Cancer Therapy Shows Encouraging Activity (12/28/2023)
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Biotech Secures Additional Funding, Extending Cash Runway (12/27/2023)
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.
Biotech Bolsters ADC Pipeline Through Atreca Asset Buy (12/26/2023)
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.
US Biotech's Anti-Fungal Wins European Approvals (12/22/2023)
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.
Biotech Co. Reports Encouraging ALS Data but FDA Wants More (12/21/2023)
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.
Pharma Co. May Have Accelerated FDA Approval in 2024 (12/20/2023)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.
Lithium Co. Will Be a Substantial Outperformer (12/19/2023)
Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp.
Bioscience Co. Expands Collaboration (12/19/2023)
This bioscience company's price target implies 680% upside, according to a Roth MKM report.
Promising Biotech Selling Way Under Cash Value (12/18/2023)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater.
Texas Biotech Advances Lead Candidate in Resistant AML (12/14/2023)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.
Biotech Seeks Approval of Synthetic Blood Vessel Graft (12/12/2023)
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino.
Drugs Show Anti-Cancer Effects on Myeloma Cells (12/06/2023)
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Antibodies from Vaccine Remain Two Years Out (12/06/2023)
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
Pharma Co. Reports Positive Data for Leukemia Combination Therapy (12/06/2023)
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.
Massachusetts Biotech Plummets as Skin Cancer Trial Fails (12/05/2023)
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.
Pharma Co.'s Partnership a Key Validation (12/04/2023)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
